 Oncogene Proteins, Fusion
"Oncogene Proteins, Fusion" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin.
| Descriptor ID |
D015514
|
| MeSH Number(s) |
D12.776.602.500.500 D12.776.624.664.500
|
| Concept/Terms |
Oncogene Proteins, Fusion- Oncogene Proteins, Fusion
- Fusion Oncogene Proteins
- Proteins, Fusion Oncogene
- Oncogene Proteins, Chimeric
- Fusion Proteins, Oncogene
- Oncogene Fusion Proteins
- Proteins, Oncogene Fusion
- Chimeric Oncogene Proteins
- Proteins, Chimeric Oncogene
- Chimeric Proteins, Oncogene
- Oncogene Chimeric Proteins
- Proteins, Oncogene Chimeric
|
Below are MeSH descriptors whose meaning is more general than "Oncogene Proteins, Fusion".
Below are MeSH descriptors whose meaning is more specific than "Oncogene Proteins, Fusion".
This graph shows the total number of publications written about "Oncogene Proteins, Fusion" by people in this website by year, and whether "Oncogene Proteins, Fusion" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 1 | 0 | 1 | | 2002 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 1 | 0 | 1 | | 2008 | 1 | 1 | 2 | | 2009 | 1 | 2 | 3 | | 2010 | 2 | 3 | 5 | | 2011 | 1 | 1 | 2 | | 2012 | 5 | 2 | 7 | | 2013 | 2 | 5 | 7 | | 2014 | 3 | 4 | 7 | | 2015 | 4 | 2 | 6 | | 2016 | 3 | 3 | 6 | | 2017 | 6 | 3 | 9 | | 2018 | 5 | 5 | 10 | | 2019 | 11 | 1 | 12 | | 2020 | 4 | 4 | 8 | | 2021 | 5 | 2 | 7 | | 2022 | 0 | 5 | 5 | | 2023 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Oncogene Proteins, Fusion" by people in Profiles.
-
Hughes CJ, Fields KM, Danis EP, Hsu JY, Neelakantan D, Vincent MY, Gustafson AL, Oliphant MJ, Sreekanth V, Zaberezhnyy V, Costello JC, Jedlicka P, Ford HL. SIX1 and EWS/FLI1 co-regulate an anti-metastatic gene network in Ewing Sarcoma. Nat Commun. 2023 07 19; 14(1):4357.
-
Chuang TP, Lai WY, Gabre JL, Lind DE, Umapathy G, Bokhari AA, Bergman B, Kristenson L, Thor?n FB, Le A, Doebele RC, Van den Eynden J, Palmer RH, Hallberg B. ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression. Proc Natl Acad Sci U S A. 2023 02 21; 120(8):e2216479120.
-
Bokhari AA, Lai WY, Le AT, Gabre JL, Chuang TP, Fransson S, Bergman B, Djos A, Chen N, Martinsson T, Van den Eynden J, Doebele RC, Palmer RH, Hallberg B, Umapathy G. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC. Lung Cancer. 2022 09; 171:103-114.
-
Wong YP, Buckley K, Iwenofu OH, Singhi A, Kahwash SB, Arnold CA, Tan GC, Arnold MA. Selective Immunoreactivity for WT1 Carboxy-Terminus Distinguishes Desmoplastic Small Round Cell Tumor From its Histologic Mimics. Pediatr Dev Pathol. 2022 Sep-Oct; 25(5):504-510.
-
Raina K, Kant R, Prasad RR, Kandhari K, Tomar M, Mishra N, Kumar R, Fox JT, Sei S, Shoemaker RH, Chen Y, Maroni P, Agarwal C, Agarwal R. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models. Mol Carcinog. 2022 07; 61(7):717-734.
-
Tsai JW, Lee JC, Hsieh TH, Huang SC, Lee PH, Liu TT, Kao YC, Chang CD, Weng TF, Li CF, Lin JC, Liang CW, Su YL, Chang IY, Wang YT, Chang NY, Yu SC, Wang JC, Huang HY. Adult NTRK-rearranged spindle cell neoplasms of the viscera: with an emphasis on rare locations and heterologous elements. Mod Pathol. 2022 07; 35(7):911-921.
-
Hsu JY, Danis EP, Nance S, O'Brien JH, Gustafson AL, Wessells VM, Goodspeed AE, Talbot JC, Amacher SL, Jedlicka P, Black JC, Costello JC, Durbin AD, Artinger KB, Ford HL. SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated state. Cell Rep. 2022 02 01; 38(5):110323.
-
Blauel ER, Laetsch TW. The promise of TRK inhibitors in pediatric cancers with NTRK fusions. Cancer Genet. 2022 04; 262-263:71-79.
-
Lind KT, Chatwin HV, DeSisto J, Coleman P, Sanford B, Donson AM, Davies KD, Willard N, Ewing CA, Knox AJ, Mulcahy Levy JM, Gilani A, Green AL. Novel RAF Fusions in Pediatric Low-Grade Gliomas Demonstrate MAPK Pathway Activation. J Neuropathol Exp Neurol. 2021 12 29; 80(12):1099-1107.
-
Jaiswal AK, Truong H, Tran TM, Lin TL, Casero D, Alberti MO, Rao DS. Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia. Sci Rep. 2021 06 23; 11(1):13158.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|